Eli Lilly is tackling a high-growth market: weight loss. The company’s weight loss portfolio brought in $10 billion in the ...

Strive Compounding Pharmacy alleges the two pharma companies are coordinating an effort to restrict compounded access.

GLP-1 agonist injections, although originally developed to treat type 2 diabetes, have changed how we approach obesity.1 The two main types now in use—semaglutide (Wegovy), produced by Novo Nordisk, ...

After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 ...

Despite ushering in the current GLP-1 era, Novo Nordisk has fallen behind its chief rival Eli Lilly, which has exceeded the ...

A single-judge bench of Delhi high court had allowed Dr Reddy’s to continue manufacturing and exporting semaglutide to ...

Once exclusively a treatment for diabetes, GLP-1 medications have gone mainstream — forcing restaurants to adjust to changing ...

NVO shares jump 9.1% as early U.S. prescriptions for oral Wegovy show strong first-week demand after its early January launch ...

South Africa is a study in contrasts. And the 2026 public health agenda is no exception. Breakthrough HIV prevention medicine ...

For the quarter ended December 31, 2025, the SMA outperformed the Index on both a gross- and net-of-fees basis due to ...